Oruka Therapeutics Rises as Investors Focus on Pipeline Data Setup

Oruka Therapeutics (ORKA) is up 7.7% today. Here is some analysis on what might have caused this price movement.

Analysis: A single fresh company announcement does not appear to explain today’s move, so the catalyst is somewhat unclear. This could be because investors are refocusing on Oruka’s strong psoriasis data, its cash position after a large spring financing, and the next round of efficacy and durability readouts expected in the second half of 2026.

Details:

Oruka’s April psoriasis update showed ORKA-001 reached a 63.5% PASI 100 rate at Week 16, giving the stock a clinical-data foundation that traders may still be rewarding.

The company has said longer-term EVERLAST-A data, including Week 28 efficacy and follow-up durability information, is expected in the second half of 2026, keeping another visible catalyst on the calendar.

Management said in May that post-offering capital is expected to fund the company through an anticipated biologics license application for ORKA-001, easing some balance-sheet pressure after an upsized $700 million public offering.

A recent analyst target increase also highlighted expectations for upcoming second-half data, which may be helping sentiment as the market looks ahead rather than reacting to new same-day news.

Sources:

Oruka Therapeutics Investor Relations, SEC, TipRanks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ORKA Insider Trading Activity

$ORKA insiders have traded $ORKA stock on the open market 57 times in the past 6 months. Of those trades, 0 have been purchases and 57 have been sales.

Here’s a breakdown of recent trading of $ORKA stock by insiders over the last 6 months:

FUNDS MANAGEMENT LLC FAIRMOUNT sold 3,553,410 shares for an estimated $300,014,406
CARL DAMBKOWSKI has made 0 purchases and 5 sales selling 140,000 shares for an estimated $8,645,748.
JOANA GONCALVES (Chief Medical Officer) has made 0 purchases and 20 sales selling 43,588 shares for an estimated $2,589,427.
ARJUN AGARWAL (Senior Vice President, Finance) has made 0 purchases and 15 sales selling 32,125 shares for an estimated $2,285,803.
LAURA LEE SANDLER (Chief Operating Officer) has made 0 purchases and 13 sales selling 16,200 shares for an estimated $1,025,878.
LAWRENCE OTTO KLEIN (Chief Executive Officer) has made 0 purchases and 2 sales selling 3,458 shares for an estimated $191,901.
PAUL T QUINLAN (General Counsel) sold 733 shares for an estimated $51,082

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$ORKA Hedge Fund Activity

We have seen 112 institutional investors add shares of $ORKA stock to their portfolio, and 39 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

COMMODORE CAPITAL LP removed 1,753,054 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $85,987,298
AVORO CAPITAL ADVISORS LLC removed 1,333,340 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $65,400,326
PARADIGM BIOCAPITAL ADVISORS LP added 610,000 shares (+35.7%) to their portfolio in Q1 2026, for an estimated $29,920,500
POINT72 ASSET MANAGEMENT, L.P. removed 600,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $29,430,000
BELLEVUE GROUP AG added 507,008 shares (+inf%) to their portfolio in Q1 2026, for an estimated $24,868,742
WESTFIELD CAPITAL MANAGEMENT CO LP added 313,130 shares (+inf%) to their portfolio in Q1 2026, for an estimated $15,359,026
AFFINITY ASSET ADVISORS, LLC removed 302,669 shares (-37.7%) from their portfolio in Q1 2026, for an estimated $14,845,914

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ORKA Price Targets

Multiple analysts have issued price targets for $ORKA recently. We have seen 8 analysts offer price targets for $ORKA in the last 6 months, with a median target of $122.5.

Here are some recent targets:

Michael Yee from UBS set a target price of $130.0 on 07/01/2026
Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $120.0 on 06/23/2026
Julian Harrison from BTIG set a target price of $151.0 on 05/14/2026
Etzer Darout from Barclays set a target price of $160.0 on 04/28/2026
Martin Fan from Wedbush set a target price of $85.0 on 04/15/2026
Yatin Suneja from Guggenheim set a target price of $125.0 on 04/13/2026
David Risinger from Leerink Partners set a target price of $86.0 on 03/16/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.